Hamlet BioPharma (HAMLET) Q1 25/26 earnings summary

Executive summary

• Completed Phase II studies in cancer and infection, secured drug production for Phase III, expanded patent portfolio, and secured up to SEK 140 million in new capital through a directed share issue and warrants.

• Achieved positive FDA feedback for Alpha1H, supporting a pivotal Phase III path in non-muscle invasive bladder cancer.

• Advanced immunotherapy pipeline, showing efficacy comparable to antibiotics and benefits in chronic pain and infection models.

• Ongoing global partnering and commercialization efforts, with active discussions for strategic collaborations.

Financial highlights

• Net sales were KSEK 0 (0) for both the group and parent company in Q1 2025/2026.

• EBITDA for the group was KSEK -9,624 (-7,802) and EBIT was KSEK -12,169 (-10,435) year-over-year.

• Net result for the group was KSEK -12,157 (-10,264) year-over-year.

• Cash and cash equivalents at quarter-end were KSEK 28,550 (16,541) for the group.

• Equity/assets ratio was 91.8% (91.4%) for the group at quarter-end.

Outlook and guidance

• Plans to conduct Phase III studies and seek market approval for Alpha1H in bladder cancer.

• Continued development of clinical programs for other indications and expansion of preclinical assets.

• Ongoing efforts to secure global partnerships and collaborations for commercialization.